• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

作者信息

Holford Nick, Nutt John G

机构信息

Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.

出版信息

Eur J Clin Pharmacol. 2008 Feb;64(2):207-16. doi: 10.1007/s00228-007-0427-9. Epub 2007 Dec 19.

DOI:10.1007/s00228-007-0427-9
PMID:18092155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3390311/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/08e67b165726/nihms273901f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/111bccf9864a/nihms273901f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/917fb8d48c71/nihms273901f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/4a1cb2c91060/nihms273901f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/dbd9742bc95d/nihms273901f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/36a8710e8a74/nihms273901f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/7d9377434fde/nihms273901f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/805c13021f50/nihms273901f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/08e67b165726/nihms273901f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/111bccf9864a/nihms273901f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/917fb8d48c71/nihms273901f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/4a1cb2c91060/nihms273901f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/dbd9742bc95d/nihms273901f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/36a8710e8a74/nihms273901f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/7d9377434fde/nihms273901f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/805c13021f50/nihms273901f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7af/3390311/08e67b165726/nihms273901f8.jpg

相似文献

1
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.疾病进展、药物作用与帕金森病：为何时间不容忽视。
Eur J Clin Pharmacol. 2008 Feb;64(2):207-16. doi: 10.1007/s00228-007-0427-9. Epub 2007 Dec 19.
2
[Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
Rev Neurol (Paris). 1999 Jan;155(1):27-33.
3
Darkening of white hair following levodopa therapy in a patient with Parkinson's disease.帕金森病患者接受左旋多巴治疗后白发变黑。
Mov Disord. 2013 Oct;28(12):1643. doi: 10.1002/mds.25696.
4
Levodopa: management of Parkinson's disease.左旋多巴：帕金森病的治疗
Mov Disord. 2002;17 Suppl 4:S23-37. doi: 10.1002/mds.5558.
5
Suicide following duodenal levodopa infusion for Parkinson's disease.
Mov Disord. 2009 Oct 15;24(13):2029-30. doi: 10.1002/mds.22708.
6
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.帕金森病、左旋多巴的作用以及早期左旋多巴帕金森病研究（ELLDOPA试验）。早期与晚期左旋多巴治疗对比
Arch Neurol. 1999 May;56(5):529-35. doi: 10.1001/archneur.56.5.529.
7
Deprenyl and levodopa and Parkinson's disease progression.司来吉兰、左旋多巴与帕金森病进展
Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228.
8
[Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].[多巴胺激动剂能否作为帕金森病早期左旋多巴的替代疗法？不能]
Neurol Neurochir Pol. 2007 Mar-Apr;41(2 Suppl 1):S10-3.
9
Slowing Parkinson's disease progression: recent dopamine agonist trials.延缓帕金森病进展：近期多巴胺激动剂试验
Neurology. 2004 Jan 27;62(2):343; author reply 343-4.
10
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.帕金森病的疾病进展与药效学——左旋多巴及其他治疗的功能保护证据
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311. doi: 10.1007/s10928-006-9012-6. Epub 2006 Apr 20.

引用本文的文献

1
Sway frequencies may predict postural instability in Parkinson's disease: a novel convolutional neural network approach.摇摆频率可能预测帕金森病的姿势不稳：一种新型卷积神经网络方法。
J Neuroeng Rehabil. 2025 Feb 18;22(1):29. doi: 10.1186/s12984-025-01570-7.
2
Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.帕金森病进展的建模及其对治疗试验中疾病修饰检测的影响。
J Parkinsons Dis. 2024;14(6):1225-1235. doi: 10.3233/JPD-230446.
3
Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).罕见神经退行性疾病中包含参数不确定性的个体疾病进展预测：常染色体隐性痉挛性共济失调 Charlevoix Saguenay (ARSACS) 的实例。
AAPS J. 2024 Apr 30;26(3):57. doi: 10.1208/s12248-024-00925-7.
4
Impact of Off-Time on Quality of Life in Parkinson's Patients and Their Caregivers: Insights from Social Media.非运动症状对帕金森病患者及其照料者生活质量的影响：来自社交媒体的见解
Parkinsons Dis. 2022 Dec 3;2022:1800567. doi: 10.1155/2022/1800567. eCollection 2022.
5
'Anxious fluctuators' a subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations.“焦虑波动者”是帕金森病的一个亚组，具有较高的焦虑和明显的开-关波动问题。
Parkinsonism Relat Disord. 2022 Dec;105:62-68. doi: 10.1016/j.parkreldis.2022.11.002. Epub 2022 Nov 4.
6
Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System.迈向帕金森病患者的改善治疗与赋权：物联网系统的设计与评估
JMIR Form Res. 2022 Jun 9;6(6):e31485. doi: 10.2196/31485.
7
A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.帕金森病中左旋多巴诱导毒性的多尺度计算模型
Front Neurosci. 2022 Apr 19;16:797127. doi: 10.3389/fnins.2022.797127. eCollection 2022.
8
Baseline predictors of progression of Parkinson's disease in a sample of Egyptian patients: clinical and biochemical.埃及帕金森病患者样本中疾病进展的基线预测因素：临床和生化因素
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):9. doi: 10.1186/s41983-022-00445-1. Epub 2022 Jan 15.
9
An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.包括左旋多巴药代动力学、多巴胺动力学、基底神经节神经传递和运动动作在内的帕金森病治疗综合模型，贯穿疾病进展过程。
J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):133-148. doi: 10.1007/s10928-020-09723-y. Epub 2020 Oct 21.
10
Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study.基于单一体固定传感器的环形步态评估得出的特发性帕金森病病情进展的潜在标志物：一项为期5年的纵向研究。
Front Hum Neurosci. 2019 Feb 19;13:59. doi: 10.3389/fnhum.2019.00059. eCollection 2019.

本文引用的文献

1
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.左旋多巴可减缓帕金森病的进展：通过临床试验模拟进行外部验证。
Pharm Res. 2007 Apr;24(4):791-802. doi: 10.1007/s11095-006-9202-3. Epub 2007 Feb 17.
2
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.帕金森病的疾病进展与药效学——左旋多巴及其他治疗的功能保护证据
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311. doi: 10.1007/s10928-006-9012-6. Epub 2006 Apr 20.
3
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.帕金森病患者左旋多巴治疗前四年的药代动力学和药效学变化。
J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):459-84. doi: 10.1007/s10928-005-0055-x.
4
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.左旋多巴药代动力学中个体内变异的重要性：一项针对帕金森病的4年队列研究
J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):307-31. doi: 10.1007/s10928-005-0039-x.
5
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.模拟帕金森病对外源性左旋多巴和内源性左旋多巴产生的短期和长期反应。
J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):243-68. doi: 10.1023/b:jopa.0000039566.75368.59.
6
More efficient clinical trials through use of scientific model-based statistical tests.通过使用基于科学模型的统计检验进行更高效的临床试验。
Clin Pharmacol Ther. 2002 Dec;72(6):603-14. doi: 10.1067/mcp.2002.129307.
7
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.早期帕金森病患者停用左旋多巴-卡比多巴和溴隐亭后临床获益丧失的定量描述。
Mov Disord. 2002 Sep;17(5):961-8. doi: 10.1002/mds.10226.
8
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.阿尔茨海默病的淀粉样蛋白假说：治疗之路上的进展与问题
Science. 2002 Jul 19;297(5580):353-6. doi: 10.1126/science.1072994.
9
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.帕金森病、左旋多巴的作用以及早期左旋多巴帕金森病研究（ELLDOPA试验）。早期与晚期左旋多巴治疗对比
Arch Neurol. 1999 May;56(5):529-35. doi: 10.1001/archneur.56.5.529.
10
Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.帕金森病患者口服左旋多巴的群体药代动力学和药效学
Eur J Clin Pharmacol. 1996;51(1):59-67. doi: 10.1007/s002280050161.